Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD.
Ingram
R H
RH
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000420:Albuterol / Q000008:administration & dosage / Q000627:therapeutic use*; D001285:Atropine / Q000008:administration & dosage / Q000627:therapeutic use; D001980:Bronchi / Q000187:drug effects; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage / Q000627:therapeutic use*; D007545:Isoproterenol / Q000008:administration & dosage / Q000627:therapeutic use; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D004338:Drug Combinations; D018727:Muscarinic Antagonists; D001285:Atropine; D009241:Ipratropium; D007545:Isoproterenol; D000420:Albuterol